U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07484113) titled 'IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD' on March 10.
Brief Summary: A single-center, Phase 1, open-label, investigator-initiated clinical trial evaluating the safety, tolerability, and preliminary efficacy of sarilumab (anti-IL-6R) monotherapy as a rescue in adult patients with belumosudil-refractory chronic graft-versus-host disease (cGVHD).
Study Start Date: May, 2026
Study Type: INTERVENTIONAL
Condition:
cGVHD
Intervention:
DRUG: Belumosudil
Belumosudil (2-(3-(4-(1H-indazol-5-ylamino) quinazolin-2-yl) phenoxy)-N-isopropylacetamide-methane sulfonic acid salt), formerly al...